Pathogenesis and mechanisms of neurodegeneration, development of therapeutic interventions for neurological disorders

Selected publications

Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease
Neurobiol Dis 2021 10.1016/j.nbd.2021.105478 

A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies
Acta Neuropathol 2021 10.1007/s00401-021-02349-5

Alpha-Synuclein Pathology Coincides With Increased Number of Early Stage Neural Progenitors in the Adult Hippocampus
Fron Cell Dev Biol 2021 10.3389/fcell.2021.691560

Optogenetic augmentation of the hypercholinergic endophenotype in DYT1 knock-in mice induced erratic hyperactive movements but not dystonia
EBioMedicine 2019 10.1016/j.ebiom.2019.02.04

Lighting Up Alpha-synuclein Oligomers
EBioMedicine 2018 10.1016/j.ebiom.2018.02.016

Polyethylenimine Nanoparticle-Mediated siRNA Delivery to Reduce α-Synuclein Expression in a Model of Parkinson’s Disease
Molecular Therapy Nucleic Acids 2017 https://doi.org/10.1016/j.omtn.2017.08.013

Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice
Neurobiology of Aging 2017 10.1016/j.neurobiolaging.2016.11.015

A GCase Chaperone Improves Motor Function in a Mouse Model of Synucleinopathy
Neurotherapeutics 2014 10.1007/s13311-014-0294-x

Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons
Neurobiology of Disease 2014 10.1016/j.nbd.2014.05.012

Genetic animal models of dystonia: Common features and diversities
Progress in Neurobiology 2014 10.1016/j.pneurobio.2014.07.002

Modelling of Parkinson's disease in mice
Lancet Neurology 2011 10.1016/s1474-4422(11)70227-7